Other research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, March 16th. Chardan Capital decreased their price objective on shares of Ritter Pharmaceuticals from $4.50 to $3.50 and set a buy rating on the stock in a research note on Thursday, March 30th. Finally, Aegis reissued a buy rating on shares of Ritter Pharmaceuticals in a research note on Tuesday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $5.21.
Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 2.3860% during midday trading on Wednesday, reaching $0.5836. The company had a trading volume of 156,907 shares. The stock’s 50 day moving average is $0.63 and its 200 day moving average is $1.89. The company’s market capitalization is $8.53 million. Ritter Pharmaceuticals has a one year low of $0.52 and a one year high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.24. Equities research analysts forecast that Ritter Pharmaceuticals will post ($1.30) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.wkrb13.com/markets/2285524/ritter-pharmaceuticals-inc-nasdaqrttr-earns-hold-rating-from-maxim-group.html.
A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period. Institutional investors own 13.77% of the company’s stock.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285524/ritter-pharmaceuticals-inc-nasdaqrttr-earns-hold-rating-from-maxim-group.html
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.